The BIOSECURE Act seeks to limit the abilities of some Chinese biotech players from doing business in the U.S., however, these firms are heavily embedded in the U.S. pharmaceutical industry, which is already struggling with widespread drug shortages now at a 20-year high.

"WuXi is heavily embedded in the U.S. medicine chest, making some or all of the main ingredients for multibillion-dollar therapies that are highly sought to treat cancers like some types of leukemia and lymphoma as well as obesity and H.I.V.," the article said. "The Congressional spotlight on the company has rattled the pharmaceutical industry, which is already struggling with widespread drug shortages now at a 20-year high. Some biotech executives have pushed back, trying to impress on Congress that a sudden decoupling could take some drugs out of the pipeline for years."